<img src="https://ml.globenewswire.com/Resource/Download/d05c16d1-5c24-4242-84b5-aea3951ca251?size=2" nborder="0" align="left" hspace="5" vspace="5" title="corvus_logo_large.jpg" alt="Corvus Pharmaceuticals, Inc."/>Company to host conference call and webcast at 4:30 pm ET / 1:30 pm PTSOUTH SAN FRANCISCO, Calif., July 30, 2026 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that the company will host a conference call and webcast on August 6, 2026 at 4:30 pm ET (1:30 pm PT) to provide a business update and report second quarter 2026 financial results. The conference call can be accessed by dialing 1-800-717-1738 (toll-free domestic) or 1-646-307-1865 (international) or by clicking on this <a href="https://www.globenewswire.com/Tracker?data=XTe8P2i269F0X5ZVpMHL3-jA-HOreEsJdluQLEErb-Axw7i9cSqmMJFKJGDODNmYIoyfB9gEzBvKfDgRK2qr6w==" rel="nofollow" target="_blank" title="link">link</a> for instant telephone access to the event. The live webcast may be accessed via the <a href="https://www.globenewswire.com/Tracker?data=8VwRCVFLVd3-SMbAgzD2s8PIqfKJYrqa9L5SnfZpJVa8euqpOyxEM8_-Zo-0XUgtbGRRk0mkZlM9UEnoNo5HDWPIWQD-M952EfdeBA1jkgk=" rel="nofollow" target="_blank" title="investor relations">investor relations</a> section of the Corvus website. A replay of the webcast will be available on Corvus’ website for 90 days. About Corvus Pharmaceuticals Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company pioneering the development of ITK inhibition as a new approach to immunotherapy for a broad range of immune diseases and cancer. The Company’s lead product candidate is soquelitinib, an investigational, oral, small molecule drug that selectively inhibits ITK. Soquelitinib is being evaluated in a registration Phase 3 clinical trial for relapsed/refractory PTCL and in a Phase 2 clinical trial for the treatment of atopic dermatitis. Its other clinical-stage candidates are being developed for a variety of cancer indications. For more information, visit <a href="https://www.globenewswire.com/Tracker?data=P4D5TJ_6AmKHo8nJNh4vvjFhYI6NnnzS0RgpVBDUg9W-Uzacx-oWwZsxhRR6guLgpmIVk1WaVvT-QoIuRYDd1__G422cvzyULr2Krnlztzk=" rel="nofollow" target="_blank" title="www.corvuspharma.com">www.corvuspharma.com</a> or follow the Company on <a href="https://www.globenewswire.com/Tracker?data=gTleGPyBDJ9kwday7K3FydGZBaJWwdmRzKTs5rxQnk6POwznJhhYCp3L-F_Z9hwuM2egsaKyME4mJ_J0QHLERSQOymOzwEICvAvaT0qcprZe1_sLD5XC6q70gGzlYhOI6KKxkmWo7Sc2sxMB4nrDtg==" rel="nofollow" target="_blank" title="LinkedIn">LinkedIn</a>. INVESTOR CONTACT: Leiv Lea Chief Financial Officer Corvus Pharmaceuticals, Inc. +1-650-900-4522 <a href="https://www.globenewswire.com/Tracker?data=8uPGHfzT9P4gecW0rhChOjGLrTOJ2oArDEQmEtMpxzPmHQyuLbQ5oVWq_AhkFJuykq3I6K9mfJrbfHaorZ6w7Lis1Lz-VeNp0aF6bBH5beY=" rel="nofollow" target="_blank" title="llea@corvuspharma.com">llea@corvuspharma.com</a> MEDIA CONTACT: Julia Stern Real Chemistry +1-763-350-5223 <a href="https://www.globenewswire.com/Tracker?data=HetbnBD465uh-lz7XAVXgyS1rQXINU5p-x8A417owvh22lAvl6pw42cSYQ-7WpV4RhxHTTb0eHnLEs2H_MC_uPgEm8VQmiVZHdqdah8fHockSbs6pO0hKXi6YCHUM7jI" rel="nofollow" target="_blank" title="jstern@realchemistry.com">jstern@realchemistry.com</a> <img alt="" src='https://ml.globenewswire.com/media/MDkyNjg4ZTAtOGZhNi00ZTdhLTkzYWUtNmM4YTg3N2M4M2QyLTEwMzc1NjUtMjAyNi0wNy0zMC1lbg==/tiny/Corvus-Pharmaceuticals-Inc-.png' referrerpolicy='no-referrer-when-downgrade' />

GlobeNewswire Inc.

Corvus Pharmaceuticals to Provide Business Update and Second Quarter 2026 Financial Results on August 6, 2026

Latest news from the world of business and finance – both local and global

MONEY FM 89.3 is Singapore's first and only Business and Personal Finance station, featuring local and international business and financial news.

MONEY FM 89.3

Discover newsletters from our DJs on LinkedIn